![Eric Venker](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 66 M $ al 31/08/2026
En la actualidad, Eric Venker es copresidente y director de operaciones de Roivant Sciences Ltd., presidente y director de operaciones de Roivant Sciences, Inc. y copresidente y director de operaciones de Roivant Sciences GmbH (ambas son filiales de Roivant Sciences Ltd.) y copresidente y director de operaciones de Montes Archimedes Acquisition Corp. Eric Venker también forma parte del consejo de administración de Arbutus Biopharma Corp, Sio Gene Therapies, Inc, Aruvant Sciences, Inc e Immunovant, Inc. Anteriormente ocupó el cargo de Presidente del Consejo de Calidad del Personal del Centro Médico de la Universidad de Columbia. Eric Venker se doctoró en la Facultad de Medicina de Yale y en la Facultad de Farmacia de St.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
ROIVANT SCIENCES LTD. 0,22 % | 30/09/2026 | 1.599.154 ( 0,22 % ) | 55 M $ | 31/08/2026 |
IMMUNOVANT INC 0,12 % | 02/10/2026 | 257.075 ( 0,12 % ) | 10 M $ | 31/08/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| IMMUNOVANT, INC. | Director Ejecutivo | 21/04/2025 |
| ROIVANT SCIENCES LTD. | Presidente | 01/01/2021 |
Roivant Sciences, Inc.
 Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets drugs | Presidente | 01/01/2021 |
Aruvant Sciences, Inc.
 Aruvant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes gene therapies for hematological diseases utilizing reduced-intensity conditioning | Director/Miembro de la Junta | - |
Roivant Sciences GmbH
 Roivant Sciences GmbH Pharmaceuticals: MajorHealth Technology Develops and markets biopharmaceutical products | Presidente | 01/01/2018 |
Roivant Social Ventures, Inc.
 Roivant Social Ventures, Inc. Roivant Social Ventures, Inc. is a not-for-profit social impact organization dedicated to advancing health equity by applying private sector strategies to biopharma innovation and healthcare delivery. The private company is based in New York, NY. The company focuses on ensuring equitable access to medicines and medical care regardless of geography, wealth, or insurance status by investing in early-stage companies developing therapies for underserved patient populations, incubating healthcare-focused social entrepreneurs, and embedding drug development education in academic institutions through fellowships and internships to promote diversity in the biopharma industry and clinical trials. Roivant Social Ventures also partners with companies, institutes, and organizations to create systemic improvements in healthcare access and delivery, with key focus areas including gene therapy access, increasing diversity in clinical trials, and fostering diversity, equity, and inclusion opportunities for future biopharma leaders. Lindsay Androski has been the CEO of the company since 2016. | Director/Miembro de la Junta | 01/01/2014 |
| Empresas | Cargo | Fin |
|---|---|---|
| SIO GENE THERAPIES INC. | Director/Miembro de la Junta | 05/04/2023 |
| ARBUTUS BIOPHARMA CORPORATION | Director/Miembro de la Junta | 25/05/2022 |
Roivant Sciences, Inc.
Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets drugs | Director Ejecutivo | 01/01/2015 |
| ░░░░░░░ ░░░░░░░░ ░░░░ | ░░░░░░░░░░ | - |
| ░░░░░░░░ ░░░░░░░░░░ ░░░░░░░ ░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 12 |
|---|---|
Arbutus Biopharma Corp.
 Arbutus Biopharma Corp. Pharmaceuticals: MajorHealth Technology Develops novel therapeutics which targets viral diseases | Health Technology |
Roivant Sciences Ltd.
 Roivant Sciences Ltd. Pharmaceuticals: MajorHealth Technology Operates as a holding company through its subsidiaries develops restorative therapies for autoimmune diseases | Health Technology |
St. Louis College of Pharmacy
 St. Louis College of Pharmacy Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Columbia University Medical Center
 Columbia University Medical Center Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Yale School of Medicine
 Yale School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Roivant Sciences GmbH
Roivant Sciences GmbH Pharmaceuticals: MajorHealth Technology Develops and markets biopharmaceutical products | Health Technology |
Sio Gene Therapies, Inc.
 Sio Gene Therapies, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops gene therapies to treat neurodegenerative diseases | Health Technology |
Roivant Sciences, Inc.
Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets drugs | Health Technology |
Aruvant Sciences, Inc.
Aruvant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes gene therapies for hematological diseases utilizing reduced-intensity conditioning | Health Technology |
Immunovant, Inc.
 Immunovant, Inc. BiotechnologyHealth Technology Develops restorative therapies for autoimmune diseases | Health Technology |
Montes Archimedes Acquisition Corp.
 Montes Archimedes Acquisition Corp. Financial ConglomeratesFinance Operates as a blank check company | Finance |
Roivant Social Ventures, Inc.
Roivant Social Ventures, Inc. Roivant Social Ventures, Inc. is a not-for-profit social impact organization dedicated to advancing health equity by applying private sector strategies to biopharma innovation and healthcare delivery. The private company is based in New York, NY. The company focuses on ensuring equitable access to medicines and medical care regardless of geography, wealth, or insurance status by investing in early-stage companies developing therapies for underserved patient populations, incubating healthcare-focused social entrepreneurs, and embedding drug development education in academic institutions through fellowships and internships to promote diversity in the biopharma industry and clinical trials. Roivant Social Ventures also partners with companies, institutes, and organizations to create systemic improvements in healthcare access and delivery, with key focus areas including gene therapy access, increasing diversity in clinical trials, and fostering diversity, equity, and inclusion opportunities for future biopharma leaders. Lindsay Androski has been the CEO of the company since 2016. |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
